Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/655—Somatostatins
  • C07K14/6555—Somatostatins at least 1 amino acid in D-form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/55—IL-2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/57545—Neuropeptide Y
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/585—Calcitonins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/595—Gastrins; Cholecystokinins [CCK]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/605—Glucagons
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/655—Somatostatins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
  • C07K14/675—Beta-endorphins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
  • C07K14/68—Melanocyte-stimulating hormone [MSH]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
  • C07K14/695—Corticotropin [ACTH]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
  • C07K7/086—Bombesin; Related peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention is concerned with modified peptides providing increased biological potency, prolonged activity and/or increased half-life thereof.
• the modification is made via coupling through an amide bond with at least one conformationally rigid substituent either at the N-terminal of the peptide, the C- terminal ofthe peptide, or a free amino or carboxyl group along the peptide chain, or at a plurality of these sites.
• peptides are rapidly degraded in a serum medium and as a result, their metabolites may sometimes end up with little or no residual biological activity.
• various techniques have been proposed. One of them is to anchor a hydrophobic chain at the N- or C-terminal of the peptidic sequence or at other residues along the peptidic chain. This technique nevertheless has limitations. For example, if the peptide comprises a long peptidic chain, the fact that a small hydrophobic group is anchored to the N- or C-terminal does not necessarily result in an increased activity ofthe peptide so-modified.
• US 6,020,311 discloses a hydrophobic growth hormone-releasing factor (GRF) analog wherein a rigidified hydrophobic moiety is coupled to the GRF peptide via an amide bond at the N-terminal of the peptide.
• GRF growth hormone-releasing factor
• Such analog is said to have an improved anabolic potency with reduced dosage, and a prolonged activity.
• the rigidified hydrophobic moiety always comprises a carbonyl group at one extremity, which means that an amide coupling thereof to the GRF can only take place at an amino site to form the required amide bond.
• trans-3-hexenoyl group attached at N-terminal position ofthe peptide sequence; - each X can be identical or independent from the others and is selected from the following list constituted by conformationally rigid moieties bearing: a) a carboxy or an amino group for coupling with the peptide sequence via an amide bond at the N-terminal of the peptide sequence, the C-terminal of the peptide sequence, at an available carboxy or amino site on the peptide sequence chain, and combinations thereof; and b) a carboxy group for coupling with the peptide sequence via an ester bond at an available hydroxy site on the peptide sequence chain, and combinations thereof; wherein, n is any digit between 1 to 5;
• X being defined as: i) a straight, substituted - o alkyl; ii) a branched, substituted -C JO alkyl; iii) a straight or branched, unsubstituted or substituted C C 10 alkene; iv) a straight or branched, unsubstituted or substituted C r C 10 alkyne; v) an unsubstituted or substituted, saturated or unsaturated C 3 -C 10 cycloalkyl or heterocycloalkyl wherein the heteroatom is O, S or N; vi) an unsubstituted or substituted C 5 -C 14 aryl or heteroaryl wherein the heteroatom is O, S or N; wherein the substituent in the definitions i) to vi) comprises one or more a) straight or branched - alkyl; b) straight or branched C C 6 alkene; c) straight or branched C[-C 6 alky
• aryl includes phenyl, naphtyl and the like;
• heterocycloalkyl includes tetrahydrofuranyl, tetrahydrothiophanyl, tetrahydrothiopyranyl, tetrahydropyranyl and partially dehydrogenated derivatives thereof, azetidinyl, piperidinyl, pyrrolidinyl, and the like;
• heteroaryl comprises pyridinyl, indolyl, fiiranyl, imidazolyl, thiophanyl, pyrrolyl, quinolinyl, isoquinolinyl, pyrimidinyl, oxazolyl, thiazolyl, isothiazolyl, isooxazolyl, pyrazolyl, and the like.
• conformationally rigid moiety means an entity having limited conformational, i.e., rotational, mobility about its single bonds. Such mobility is limited, for example, by the presence of a double bond, a triple bond, or a saturated or unsaturated ring, which have little or no conformational mobility. As a result, the number of conformers or rotational isomers is reduced when compared, for example, with the corresponding straight, unsubstituted and saturated aliphatic chain.
• the conformationally rigid moiety may be hydrophobic, although this is not a prerequisite.
• the peptide sequence is selected from the group consisting of Growth hormone releasing factor (GRF), Somatostatin, Glucagon-like peptide 1 (7-37), amide human (GLP-1), hGLP-1 (7-36) NH 2 Parathyroid hormone fragments such as (PTH 1-34), Adrenocorticotropic hormone (ACTH), Osteocalcin, Calcitonin, Corticotropin releasing factor, Dynorphin
• MSH Melanocyte Stimulating Hormone
• Neuromedin B Human Neuropeptide Y, Human Orexin A, Human Peptide YY, Human Secretin, Vasoactive Intestinal peptide (VIP), Antibiotic peptides (Magainin 1, Magainin 2, Cecropin A, and Cecropin B), Substance P (SP), Beta Casomorphin-5, Endomo ⁇ hin-2, Procolipase, Enterostatin, gastric inhibitory peptide, Chromogranin
• Vasostatin I & II Procalcitonin, ProNCT, ProCGRP, JX8 (monocyte-derived),
• GCP-2 PF4, IP-10, MIG, SDF-l , GRO- ⁇ , I-TAC, RANTES, LD78, MTP-l ⁇ ,
• amino acids are identified in the present application by the conventional three-letter abbreviations as indicated below, which are as generally accepted in the peptide art as recommended by the IUPAC-IUB commission in biochemical nomenclature:
• the present invention relates to the use of at least one conformationally rigid moiety, to produce a new family of peptides with enhanced pharmacological properties.
• modified peptides of the present invention are prepared according to the following general method, well known in the art of solid phase synthesis.
• Conformationally rigid moieties comprising a carboxy group are used for anchoring to amino groups such as those found on the lysine side chain as well as the N-terminus of peptides. Those comprising an amino group are used for anchoring to carboxyl groups such as those found on the aspartic or glutamic acid side chains or the C-terminus of peptides.
• the anchoring reaction is preferably performed on a solid phase support (Merrifield R.B. 1963, J. Am. Chem. Soc.1963. 85, 2149 and J Am. Chem. Soc, 1964.
• the preferred working temperatures are between 20°C and 60°C.
• the anchoring reaction time in the case of the more hydrophobic moieties varies inversely with temperature, and varies between 0.1 and 24 hours.
• Fmoc deprotections were accomplished with piperidine 20% solution in DMF in three consecutive steps. Always under nitrogen scrubbing, a first solution of piperidine 20% was used for lmin. to remove the major part of the Fmoc protecting groups. Then, the solution was drained, and another fresh piperidine 20% solution was introduced this time for 3min., drained again and finally another solution of piperidine 20% for lOmin. The peptide-resin was then washed 4 times successively with 50 mL of DMF under nitrogen scrubbing. After completion of the synthesis, the resin was well washed with DMF and DCM prior to drying.
• the peptide-resin (X mmol) was then introduced in DCM under nitrogen scrubbing and after 10 min.
• the PdCl 2 (PPh 3 ) 2 (X mmol x 0.05 / 0.05 eq) palladium(II) bis-triphenylphosphine) was added to the mixture (Burger H., Kilion W., J Organometallics, 1969, 18:299).
• the (CH 3 CH 2 CH 2 ) 3 SnH (X mmol x 6 / 6eq ) tributyltinhydride
• the invention is not limited to any particular peptide sequence.
• Preferred peptide sequences R 1 comprise those with therapeutic properties, as well as functional derivatives or fragments thereof.
• the therapeutic properties of such peptides include, without limitation, treatment of bone diseases including osteoporosis, postmenopausal osteoporosis and bone deposits, cancer treatment, regulating blood glucose, type II diabetes, treatment to to enhance mucosal regeneration in patients with intestinal diseases, treatment for diseases related to inflammatory responses, obesity treatment, treatment for autism and pervasive development disorders, hyperproliferative skin conditions, aging, altering the proliferation of peripheral blood mononuclear cells, regulation of myometrial contractility and of prostaglandin release, stimulation of ACTH release, inhibition of interleukin-8 production, stimulation of acid release, enhancement of mucosal regeneration in patients with intestinal diseases, treatment for hormone-dependent diseases and conditions including for hormone-dependent cancers, modulation of melanocyte information process, involved in pressure and volume homeostasis, regulation of exocrine and endocrine secretions, smooth muscle contraction, feeding
• GEF Growth hormone releasing factor
• Xaa is Tyr or His; Xaa, is Val or Ala: Xaa 8 is Asn or Ser; Xaa I3 is Val or He; Xaa 15 is Ala or Gly; Xaa 18 is Ser or Tyr; Xaa 24 is Gin or His; Xaa 25 is Asp or Glu; Xaa 27 is Met, He or Nle; and Xaa 28 is Ser or Asn.
• Xaa 12 is Tyr or Ser.
• Glucagon-like peptide 1 (7-37), (amide human (hGLP-1)):
• PTH 1-34 Parathyroid hormone fragments
• Xaa x is Ser or Ala
• Xaa 5 is Ile or Met
• Xaa 7 is Leu or Phe
• Xaa 13 is Lys or Glu
• Xaa 15 is Leu or Arg
• Xaa 16 is Asn or Ala or Ser or His
• Xaa is Ser of Thr
• Xaa 18 is Met or Val or Leu
• Xaa 21 is Val or met or Gin
• Xaa 22 is Glu or Gin or Asp
• Xaa 2S is Arg or Gin
• Xaa 26 is Lys or Met
• Xaa 33 is Asn or Ser
• Xaa 34 is Phe or Ala.
• Adrenocorticotropic hormone (ACTH):
• Xaa 13 is Val or Met
• Xaa x 5 is Lys or Arg
• Xaa 20 is Val or He
• Xaa 26 is Gly or Ser; Xaa 27 is Ala or Phe or Val;
• Xaa 28 is Glu or Gin
• Xaa 29 is Asp or Asn or Glu
• Xaa 31 is Ser or Thr
• Xaa 32 is Ala or Val or Ser
• Xaa 34 is Ala or Asn or Gly
• Xaa 35 is Phe or Met
• Xaa 36 is Pro or Gly
• Xaa 37 is Leu or Val or Pro
• o Xaa 39 is Phe or Val or Leu.
• Xaa 52 is Tyr or Asp or Asn
• Xaa 53 is Gin or His or Asn
• Xaa 54 is T ⁇ or Gly
• Xaa 59 is Val or Ala
• o Xaa 68 is Arg or Lys or His
• Xaa 77 is Asp or Asn
• Xaa 89 is Glu or Asp; Xaa 92 is Arg or Lys;
• Xaa 94 is Phe or He
• Xaa 97 is Pro or Thr.
• Xaa 86 is Gly or Ser or Ala
• Xaa 87 is Asn or Ser
• Xaa 92 is Met or Val
• Xaa 95 is Thr or Lys
• Xaa 96 is Tyr or Leu
• Xaa 97 is Thr or Ser
• Xaa 98 is Gin or Lys
• Xaa 99 is Asp or Glu
• Xaa 100 is Phe or Leu
• Xaa 101 is Asn or His
• Xaa 102 is Lys or Asn
• Xaa 103 is Phe or Leu
• Xaa 104 is His or Gin
• Xaa 106 is Phe or Tyr
• Xaa 107 is Pro or Ser
• Xaa 108 is Gin or Gly or Arg
• Xaa 109 is Thr or He
• Xaa 110 is Ala or Gly or Ser or Asp or Asn;
• Xaa ⁇ n is He or Phe or Val or Thr;
• Xaa 113 is Val or Ala or Ser
• Xaa 114 is Gly or Glu
• Xaa U5 is Ala or Thr.
• Xaa 101 is Ala or Pro
• Xaa 102 is Arg or Gly.
• Dynorphin A H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-T ⁇ -Asp-Asn-Gln-OH
• Xaa 243 is Ser or Pro
• Xaa 245 is Lys or Arg
• Xaa 251 is Val or Met
• Xaa 259 is He or Val
• Xaa 262 is Ala or Thr or Ser or Val
• Xaa 263 is Tyr or His
• Xaa 267 is Glu or Leu or Gin or His.
• Bi Gastrin-1 pXaa 59 -Leu-Gly-Xaa 62 -Gln-Xaa 64 -Xaa 65 -Xaa 66 -Xaa 67 -Xaa 68 -Xaa 69 -Ala-Asp-Xaa 72 - Xaa 73 -Lys-Lys-Xaa 76 -Xaa 77 -Pro-Xaa 79 -Xaa 80 -Glu-Xaa 82 -Glu-Glu-Xaa 85 -Ala-Tyr-Gly- T ⁇ -Met-Asp-Phe-NH 2 wherein,
• Xaa 59 is Glu or Gin
• Xaa 62 is Pro or Leu
• Xaa 64 is Gly or Asp
• Xaa 65 is Pro or Ser
• Xaa 66 is Pro or Gin
• Xaa 67 is His or Gin
• Xaa 68 is Leu or Met or Phe or Gin
• Xaa 69 is Val or He; Xaa 72 is Pro or Leu;
• Xaa 73 is Ser or Ala
• Xaa 76 is Gin or Glu
• Xaa 77 is Gly or Arg
• Xaa 79 is T ⁇ or Pro or Arg
• Xaa 80 is Leu or Val or Met
• Xaa 82 is Glu or Lys
• Xaa 85 is Glu or Ala.
• Xaa 152 is Ser or Thr
• Xaa 153 is Asp or Ser
• Xaa 154 is Glu or Asp
• Xaa 155 is Met or Phe
• Xaa 156 is Asn or Ser
• Xaa 157 is Thr or Lys
• Xaa 1S8 is He or Val or Ala
• Xaa 161 is Asn or He or His or Ser; Xaa 162 is Leu or Lys;
• Xaa 64 is Ala or Thr
• Xaa 6s is Arg or Gin or Lys
• Xaa g 6 is Asp or Glu
• Xaa 68 is He or Leu
• Xa 69 is Asn or Asp
• Xaa 71 is Leu or He
• Xa 72 is He or Leu
• Xa 73 is Gin or Asn or His
• Xa 75 is Lys or Pro
• Xaa 76 is He or Val
• Xaa 77 is Thr or Lys
• Xaa 78 is Asp or Glu.
• Xa j is pGlu, 5-oxoPro or Gin.
• MSH Melanocyte Stimulating Hormone
• Xaa 135 is Met or He
• Xaa 142 is Gly or Ser.
• Neuromedin B
• Human Orexin A pGlu-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu- Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH 2
• Human Peptide YY H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn- Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-
• VIP Vasoactive Intestinal peptide
• Antibiotic peptides such as:
• Ala-Lys Cecropin B Lys-T ⁇ -Lys-Val-Phe-Lys-Lys-Ile-Glu-Lys-Met-Gly-Arg-Asn-Ile-Arg-Asn-
• Beta Casomorphin-5 isomorphin-5
• Chemokine family CXC-group: IL8(monocyte-derived):
• MCP-2 GlnProSerAspValSerlleProIleThrCys...
• MCP-3 GlnProValGlylleTAsnSeerThrThrCys...
• the peptide is substituted with one or more conformationally rigid moieties.
• Preferred structures of the corhOrmationally rigid moieties comprise those with a double bond, a triple bond or a saturated or unsaturated ring.
• modified peptides are those wherein the peptide sequence is the sequence of a natural peptide.
• R is hydrogen, CH 3 or CH 2 CH 3
• An another preferred embodiment of the present invention is constituted by those peptides wherein the peptide sequence is PTH 1-34 and at least one conformationally rigid moiety is coupled with said PTH 1-34 peptide sequence via an amide bond at different positions as follows: Position conformationally rigid moieties
• a further preferred embodiment of the present invention is constituted by those peptides wherein the peptide sequence is GLP-1 and at least one conformationally rigid moiety is coupled with said GLP-1 peptide sequence via an amide bond at different positions as follows:
• modified peptides are those peptides wherein;
• the peptide sequence is GLP-2 and at least one conformationally rigid moiety is coupled with said GLP-2 peptide sequence via an amide or ester bond at different positions ofthe peptide sequence;
• the peptide sequence is Enterostatin and at least one conformationally rigid moiety is coupled with said Enterostatin peptide sequence via an amide bond at different positions ofthe peptide. sequence; - the peptide sequence is NPY and at least one conformationally rigid moiety is coupled with said NPY peptide sequence via an amide or ester bond at different positions ofthe peptide sequence;
• the peptide sequence is NPYY and at least one conformationally rigid moiety is coupled with said NPYY peptide sequence via an amide or ester bond at different positions ofthe peptide sequence;
• the peptide sequence is Secretin and at least one conformationally rigid moiety is coupled with said Secretin peptide sequence via an amide or ester bond at different positions ofthe peptide sequence;
• the peptide sequence is Vasoactive Intestinal Peptide and at least one conformationally rigid moiety is coupled with said Vasoactive Intestinal
• the peptide sequence is Gastrin Inhibitory Peptide and at least one conformationally rigid moieties is coupled with said Gastrin Inhibitory Peptide sequence via an amide or ester bond at different positions of the peptide sequence;
• the peptide sequence is Vasostatin H and at least one conformationally rigid moiety is coupled with said Vasostatin H peptide sequence via an amide or ester bond at different positions ofthe peptide sequence;
• the peptide sequence is RANTES and at least one conformationally rigid moiety is coupled with said RANTES peptide sequence via an amide or o ester bond at different positions of the peptide sequence;
• the peptide sequence is Eotaxin and at least one conformationally rigid moiety is coupled with said Eotaxin peptide sequence via an amide or ester bond at different positions ofthe peptide sequence.
• the conformationally rigid moiety is preferably coupled with said peptide sequence via an amide bond at the N- terminal.
• modified peptides according to the invention wherein the o conformationally rigid moiety is the formula referenced 60 in the description, are of a particular interest.
• modified peptides of the present invention can be a ⁇ iministered in various ways, such as for example, intravenously, subcutaneously, intradermally, transdermally, intraperitoneally, orally, or topically.
• the modified peptides of the present invention can also be administered by inhalation, when in a powder form or aerosol form.
• pharmaceutically acceptable carriers for delivery of modified peptides of the present invention include, without limitation, liposome, nanosome, patch, implant or any delivery devices.
• carboxy and amino sites can be available on the peptide chain.
• the peptide chain comprises amino acids provided with a carboxylic acid side chain such as aspartic acid and glutamic acid
• additional carboxy sites will therefore be available on the chain for amidation.
• the peptide chain comprise amino acids with a carboxamide side chain such as asparagine and glutamine, these also provide additional carboxy groups for amidation by a conformationally rigid moiety, provided that they are accessed synthetically via the corresponding aspartic and glutamic acids.
• the peptide comprises amino acids provided with a basic side chain such as arginine, histidine or lysine
• additional amino sites will then be available on the chain for amidation by a conformationally rigid moiety.
• the peptide chain may also include both acidic and basic amino acids, meaning that the conformationally rigid substituents could be coupled to the peptide chain via the N-terminal, the C-terminal, a carboxy site on the peptide chain, an amino site on the peptide chain, or a plurality of these sites.
• At least one of the following conformationally rigid moiety is coupled with the GLP-1 peptide sequence via an amide bond at different positions as follows.
• the peptides were cleaved using a TFA cocktail (92% TFA, 2% ethanedithiol, 2% thioanisole, 2% triisopropylsilane, 2% water, 2% (w/v) phenol) for 2 hours. All the analogs have been purified by reverse-phase HPLC. They have been analyzed by analytical HPLC and by MS (MALDI-TOF).
• GLP-1 analogs are well known to the person skilled in the art and is further illustrated by the general references Fmoc Solid Phase Peptide Synthesis. A Practical Approach (2000). Chan, W.C. and White, P.D., Oxford University Press, New York, USA, 346p which are inco ⁇ orated by reference.
• peptides including wild-type GLP-1 (7-37), were tested in the OGTT test at 3 different concentrations: 1, 5 and 10 ug per mouse, h a first set of experiments 5 (study A), peptide 3 was tested in comparison with vehicle and hGLP-1 (7-37). In a second set of experiments (study B), peptides 1 and 2 were tested in comparison with vehicle and hGLP-1 (7-37).
• Peptide #2 ((+,-)-cis-2-Ethylcyclopropylacetic acid-His 7 )-hGLP-l (7-37)
• Peptide #3 (Hexenoyl-trans-3-His 7 )-hGLP-l (7-37)
• peptide 2 (study B, Fig.2) was even more potent than peptide 3, being able to totally prevent the glucose response both at the 5 ug and the 10 ug doses (5 ug: -17 + 67 mMxl20 min; 10 ug: 61 ⁇ 64 mMxl20 min).
• the GLP-1 analog corresponding to peptide 2 was identified with marked increased biological potency over the wild type GLP-1 (7- 37), because of this increased potency, this peptide may have clinical usefulness in treating states of insulin resistance associated with pathologies such as type II diabetes.
• At least one of the following conformationally rigid moiety is coupled with the PTH 1-34 peptide sequence via an amide bond at different positions as follows.
• Somatostatin analogs h accordance with the present invention at least one of the following conformationally rigid moiety is coupled with the somatostatin peptide sequence via an amide bonds at different position as follows.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Toxicology (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Emergency Medicine (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22832986

Family Applications (1)

Country Status (8)

Cited By (45)

Families Citing this family (32)

Family Cites Families (11)

• 2001
  • 2001-08-02 BR BR0113178-8A patent/BR0113178A/pt not_active Application Discontinuation
  • 2001-08-02 CA CA002417100A patent/CA2417100A1/en not_active Abandoned
  • 2001-08-02 JP JP2002515924A patent/JP2004509079A/ja active Pending
  • 2001-08-02 AU AU2001279526A patent/AU2001279526A1/en not_active Abandoned
  • 2001-08-02 EP EP01957662A patent/EP1305338A2/en not_active Withdrawn
  • 2001-08-02 CN CN01813865A patent/CN1454214A/zh active Pending
  • 2001-08-02 WO PCT/CA2001/001119 patent/WO2002010195A2/en not_active Ceased
  • 2001-08-02 US US10/343,654 patent/US20030204063A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events